AllGen Financial Advisors Inc. Buys 357 Shares of CVS Health Co. (NYSE:CVS)

AllGen Financial Advisors Inc. increased its stake in CVS Health Co. (NYSE:CVS) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,720 shares of the pharmacy operator’s stock after buying an additional 357 shares during the quarter. CVS Health comprises approximately 1.8% of AllGen Financial Advisors Inc.’s holdings, making the stock its 12th largest holding. AllGen Financial Advisors Inc.’s holdings in CVS Health were worth $3,531,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in CVS Health by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 117,162,626 shares of the pharmacy operator’s stock valued at $8,180,295,000 after buying an additional 485,744 shares in the last quarter. FMR LLC boosted its holdings in shares of CVS Health by 29.1% in the third quarter. FMR LLC now owns 27,487,238 shares of the pharmacy operator’s stock valued at $1,919,159,000 after purchasing an additional 6,194,441 shares during the period. Northern Trust Corp grew its stake in CVS Health by 2.2% in the third quarter. Northern Trust Corp now owns 14,214,296 shares of the pharmacy operator’s stock worth $992,442,000 after purchasing an additional 305,564 shares in the last quarter. Royal Bank of Canada raised its position in CVS Health by 2.2% during the 3rd quarter. Royal Bank of Canada now owns 14,136,920 shares of the pharmacy operator’s stock valued at $987,041,000 after purchasing an additional 303,512 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of CVS Health by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 12,717,825 shares of the pharmacy operator’s stock worth $864,821,000 after buying an additional 324,391 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

Shares of CVS traded up $0.75 during trading hours on Friday, reaching $55.90. 23,946,075 shares of the company traded hands, compared to its average volume of 12,498,538. The stock has a market capitalization of $70.18 billion, a P/E ratio of 9.82, a P/E/G ratio of 0.88 and a beta of 0.56. The company has a quick ratio of 0.63, a current ratio of 0.81 and a debt-to-equity ratio of 0.78. The business has a fifty day moving average price of $72.77 and a 200-day moving average price of $73.29. CVS Health Co. has a 12-month low of $53.70 and a 12-month high of $83.25.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The firm had revenue of $88.44 billion during the quarter, compared to analyst estimates of $89.33 billion. During the same period in the prior year, the company posted $2.20 earnings per share. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. Equities analysts anticipate that CVS Health Co. will post 7.03 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.76%. The ex-dividend date was Friday, April 19th. CVS Health’s payout ratio is 46.75%.

Insider Transactions at CVS Health

In related news, EVP Prem S. Shah sold 29,473 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the transaction, the executive vice president now directly owns 39,765 shares in the company, valued at $3,059,916.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Prem S. Shah sold 29,473 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the sale, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 1,000 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was bought at an average cost of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now directly owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The disclosure for this purchase can be found here. Company insiders own 0.24% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on CVS shares. Royal Bank of Canada decreased their price objective on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a report on Thursday, February 8th. Mizuho lowered their price target on shares of CVS Health from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Thursday. Barclays cut their price objective on shares of CVS Health from $78.00 to $63.00 and set an “equal weight” rating on the stock in a report on Thursday. Bank of America lowered their target price on CVS Health from $95.00 to $77.00 and set a “buy” rating for the company in a report on Thursday. Finally, Wells Fargo & Company reduced their price target on CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 8th. Eight equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $80.35.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.